The Efficacy and Safety of Iparomlimab and Tuvonralimab Injection Combined With Chemotherapy as the First-line Treatment for Esophageal Squamous Cell Carcinoma

NCT07290010 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

25

Enrollment

OTHER

Sponsor class

Conditions

Esophageal Squamous Cell Carcinoma (ESCC)

Interventions

DRUG: Iparomlimab and Tuvonralimab combined with chemotherapy

Sponsor

Hebei Medical University Fourth Hospital